Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at firstname.lastname@example.org
Natalizumab Provides Superior 'Feel Good' Experience in MS Over Other Treatments
Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.
Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS
The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.
Ocrelizumab Has Similar Effects in MS With Shorter Infusion Time
The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.
Elevated Plasma NfL Levels Linked to Worse Disability in Multiple Sclerosis
Plasma neurofilament light chain (pNfL) may serve as a prognostic tool to assess the risk of developing permanent disability in multiple sclerosis.
The Importance of Interdisciplinary Care in MS
The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.
Glatopa Has Similar Outcomes and Cost Compared With Copaxone
The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.
Tardive Dyskinesia Worsens Quality of Life in Patients With Psychiatric Disorders
The data support the need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening and diagnosing patients.
Residential Segregation Leads to Worse Cognition in Black Individuals
The association between black individuals and processing speeds may explain the black-white disparities in dementia risk at older age.
Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy
The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.
Risk of Cardiovascular Disease Increased in Those With Multiple Sclerosis
Women with multiple sclerosis had a greater risk of macrovascular disease than men, which was consistent with previous studies.
Recommendations for Prehospital Stroke Care During COVID-19 Published
During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around.
Adjusting Epilepsy Care During the COVID-19 Pandemic
The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.
AID-P Provides Most Accurate Differentiator of Parkinson Disease
Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.
FT218 Meets Primary End Point in Phase 3, Lowers Weekly Cataplexy Attacks
Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Earlier Treatment Linked to Better Outcomes in Sleep-Disordered Breathing
System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.
Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy
The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.
Study Identifies Inconsistencies Among Genetic Testing for Epilepsy
Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.
Cold Extremities Linked to More Frequent Migraine Attacks in Women
Women with migraine with cold extremities had higher attack frequencies, which data suggest stems partly from sleep disturbances.
Clinicians Report Inconsistencies in Treating Migraine With PREEMPT Protocol
The wide variance in onabotunlinumtoxinA use for migraine prevention raises the question of whether evidence-based advisory statements might be more helpful than a proscriptive protocol.
Cenobamate Reduces Seizure Frequency Regardless of Concomitant AEDs
Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.
Bridging Therapy Effective for Stroke With M1 Occlusions
The first study to assess the effect of endovascular therapy added on to intravenous thrombolysis uncovered more evidence of its effect on specific occlusions rather than overall outcomes.
Inotersen Slows Progression of hATTR Amyloidosis
Early treatment with Ionis Pharmaceuticals’s inotersen resulted in greater long-term disease stabilization than delayed initiation.
Vitamin D, Smoking Conversely Predict Cognitive Function in Multiple Sclerosis
Data led the authors to believe that vitamin D might have neuroprotective properties and that levels may be a prognostic marker of long-term cognition and neuroaxonal integrity.
CMSC, National MS Society Release Multiple Sclerosis Physical Activity Recommendations
The exercise and physical activity recommendations were tailored to individuals with differing disability levels on the Expanded Disability Status Scale.
Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function
Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.
FDA Approves Bafiertam Fumarate Bioequivalent for Relapsing Multiple Sclerosis
Banner Life Science’s novel fumarate bioequivalent alternative to Tecfidera (dimethyl fumarate; Biogen) enters the market as a new oral treatment option for relapsing forms of multiple sclerosis.
Recommendations for Epilepsy Care During COVID-19
An emphasis on at-home care as well as reducing the risk of seizure exacerbation are among a list of notable recommendations to help optimize clinical care for patients with epilepsy amidst the COVID-19 pandemic.
Galcanezumab Has Significant Impact for Patients With Refractory Migraine
The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.
Lasmiditan Improves Migraine-Related Disability
The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.
Risdiplam Demonstrates Significant Motor Milestones in Infants with Type 1 SMA
In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.
2 Commerce Drive Cranbury, NJ 08512